These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 7198461)

  • 1. Toxicological studies of plafibride. Part 4: Interaction of plafibride with other drugs.
    Zapatero J; Basi N; Vilageliu J; Sanfeliu C; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1835-8. PubMed ID: 7198461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicological studies of plafibride. Part 1: Acute toxicity and its determination after several administrations of plafibride.
    Zapatero J; Sanfeliu C; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1816-9. PubMed ID: 7198458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicological studies of plafibride. Part 2: Subacute and subchronic toxicity in rats and chronic toxicity in dogs.
    Zapatero J; Sanfeliu C; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1819-30. PubMed ID: 7198459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypolipemic activity of plafibride.
    Bruseghini L; Vilageliu J; Bagaria A
    Arzneimittelforschung; 1981; 31(10a):1796-800. PubMed ID: 7198456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic approach of plafibride in rat.
    Zapatero D; Vilageliu J; Torres A; Ribalta JM; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1800-4. PubMed ID: 7198457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological activities and side effects of plafibride.
    Gras J; Basi N; Zapatero J; Bermejo P; Gimenez F; Beascoa E; Llenas J; Bargalló MA; Giráldez A; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1808-16. PubMed ID: 6976173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicological studies of plafibride. Part 3: Study of teratogenic activity in rats and rabbits.
    Sanfeliu C; Zapatero J; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1831-4. PubMed ID: 7198460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet antiaggregant activity of plafibride ex vivo in rat, dog and rabbit.
    Bruseghini L; Vilageliu J; Freixes J
    Arzneimittelforschung; 1981; 31(10a):1790-5. PubMed ID: 6797443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioavailability of plafibride in healthy volunteers.
    Santaniello E; Conti F; Vilageliu J; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1850-2. PubMed ID: 7198464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plafibride tolerance trial in healthy volunteers.
    Dalmau J; Vicens B; Zapatero J; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1845-9. PubMed ID: 7198463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of plafibride on erythrocyte deformability.
    Vilageliu J; Freixes J; Bruseghini L
    Arzneimittelforschung; 1983; 33(3):401-4. PubMed ID: 6683514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacterial mutation test on plafibride.
    Richold M; Jones E
    Arzneimittelforschung; 1981; 31(10a):1838-40. PubMed ID: 7032531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plafibride tolerance trial at increasing doses in healthy volunteers.
    Dalmau J; Vicens B; Zapatero J; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1840-4. PubMed ID: 7198462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trials of plafibride in geriatric patients.
    Demichelis Genesio MA; Bracons R; Vicens B; Zapatero J; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1852-5. PubMed ID: 7198465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and pharmacological evaluation of N'-morpholinomethylurea derivatives with platelet antiaggregant activity.
    Ribalta JM; Artús JJ; Salvador L; Roma E; Vilageliu J; Freixes J; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1782-6. PubMed ID: 6797442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of plafibride, an antiplatelet and hypolipemic agent, on prostacyclin and thromboxane synthesis, 3',5'-cyclic AMP phosphodiesterase activity and serum clearance of a lipid emulsion.
    Vilageliu J; Freixes J; Giráldez A; Bermejo P; Basi N; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1805-7. PubMed ID: 6274363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical research into the hypolipemic and platelet antiaggregant activity of plafibride, Carried out in double-blind conditions and in comparison with clofibrate.
    Palmieri B; Gasparini Casari M; DiBlasio P; Zirilli E
    Arzneimittelforschung; 1981; 31(10a):1863-6. PubMed ID: 7032534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plafibride: clinical trial of a new platelet antiaggregating agent.
    Olivella J; Vicens B
    Arzneimittelforschung; 1981; 31(10a):1856-8. PubMed ID: 7032532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physico-chemical and analytical studies on plafibride.
    Torres A; Ristol P; Ribalta JM
    Arzneimittelforschung; 1981; 31(10a):1786-90. PubMed ID: 7198455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind study on the activity of plafibride in the treatment of type IV hyperlipoproteinemia.
    Ferreira IJ; del Rio A; González-Viejo N; Vicens B
    Arzneimittelforschung; 1981; 31(10a):1859-62. PubMed ID: 7032533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.